Navigation Links
Parion Sciences and Kainos Medicines Sign Clinical Development Agreement for Novel Dry Mouth Treatment
Date:10/28/2008

Kainos to Fund Up to $25 Million to Advance P-552

DURHAM, N.C., Oct. 28 /PRNewswire/ -- Parion Sciences, Inc. and Kainos Medicines, Inc. today announced that they have entered into an agreement to co-develop Parion's proprietary epithelial sodium channel blocker, P-552, for the treatment of dry mouth associated with primary Sjogren's syndrome.

Under the agreement, the companies will collaborate in the clinical development of P-552. Kainos will provide funding to help advance the program through the end of Phase II clinical testing, supplying up to $25 million upon completion of all milestones. Parion will be responsible for the oversight of the clinical development program while Kainos will provide CMC (chemistry, manufacturing and controls) expertise. Upon the successful completion of the Phase II program, Parion and Kainos will determine the Phase III clinical development and commercialization of P-552.

In a Phase I/II clinical study completed in April 2008, P-552 was found to be safe and tolerable in subjects with primary Sjogren's disease. The study demonstrated promising results in several key quality of life parameters including mouth dryness, mouth comfort and ability to sleep, as assessed by Visual Analogue Scale (VAS).

"Sjogren's syndrome patients are seeking effective relief of their dry mouth. By combining the talents and expertise of two proven development teams, we believe we can accelerate the clinical development of P-552 to effectively address this unmet need," said M. Ross Johnson, Parion Chief Executive Officer. "This partnership represents the second application of our portfolio of sodium channel blockers as we continue to expand Parion's unique technology and novel compound library into other diseases requiring mucosal hydration."

"I am very pleased that Kainos and Parion will be working together on the development of P-552," said M.C. Kang, Kainos Chief Executive Officer. "Strategically, each partner brings its complementary expertise to the collaboration. This will provide a comprehensive and complete development program for P-552 and support the business strategy of Kainos Medicines."

Epithelial sodium channel (ENaC) blockers, such as P-552, are unique therapeutic agents developed to maintain and stimulate hydration on the body's mucosal surfaces, including those of the lung, mouth, nose, eye and gastrointestinal tract. Improving the mucosal hydration in the mouth addresses quality of life problems associated with oral dryness caused by Sjogren's syndrome.

Sjogren's syndrome is a chronic disorder that occurs when a person's immune system attacks and destroys moisture-producing glands, including the salivary and tear glands. There are currently no specific topical pharmaceutical medications to alleviate the symptoms of dry mouth associated with Sjogren's syndrome, which can cause difficulty with chewing and swallowing, decreased sense of taste, hoarseness, coughing and an increase in dental cavities.

About Parion Sciences

Based in Durham, NC, Parion Sciences is a privately-held, development- stage pharmaceutical company that is leveraging its proprietary small molecule chemistry and epithelial biology expertise to discover and develop an innovative pipeline of therapies for diseases resulting from the failure of the body's mucosal defenses, including chronic obstructive pulmonary disorder (COPD), cystic fibrosis, bronchiactesis and Sjogren's syndrome. Parion's lead product candidate, P-552, is currently in Phase II clinical development for the treatment dry mouth associated with Sjogren's syndrome. The company is also collaborating with Gilead Sciences on the development of drug candidates for pulmonary diseases. For more information, please visit http://www.parion.com.

About Kainos Medicines

Based in Seoul, South Korea, Kainos Medicines is a privately-held company that focuses on the in-licensing and development through proof of concept of diverse and promising, early-stage drug candidates for clinically relevant targets. Subsequent to proof of concept, the company will seek strategic partnerships to complete the development of successful drug candidates through global regulatory approval and commercialization. Kainos Medicines USA, Inc., based in Morrisville, NC, provides the preclinical and clinical development activities to obtain the safety and efficacy data for the Kainos drug candidates.


'/>"/>
SOURCE Parion Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
2. Human Pheromone Sciences, Inc. - Shareholder Update
3. Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company
4. Isis Ibis Biosciences Subsidiary Highlights the Power of the Ibis T5000 Pathogen Identification and Characterization System at the ICAAC/IDSA Meeting
5. Caliper Life Sciences Third Quarter 2008 Financial Results Conference Call Notice
6. Advanced Life Sciences Completes Debt Transaction
7. LI-COR Biosciences and Euthanex Corporation Provide Anesthesia System for Small Animal Imaging
8. MedTechIQ Selects TheBrain to Visualize Expansive Biointellingence Database and Connect the Dots Between Life Sciences, Medicine and Venture Capital
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
10. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
11. Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):